About
Roman currently serves as the CEO of Janpix, an oncology-focused start-up. He was formerly an advisor to Index Ventures and, before that, a Principal at Index, where among others he invested in and represented the firm on the boards of GlycoVaxyn (sold to GlaxoSmithKline), Versartis (Nasdaq: VSAR), and Novocure (Nasdaq: NVCR). He started his career at Boehringer Ingelheim Pharmaceuticals in Connecticut where he was leading development projects in oncology, inflammation and cardiovascular disease, advancing several compounds from pre-clinical to clinical stage. Roman received a PhD from MIT as well as an MBA from NYU’s Stern School of Business. He has authored or co-authored numerous publications in prestigious journals as well as issued patents.
Position in the VCSift Database
- • 3,360 investors hold the CEO role in VCSift. Roman Fleck is one of them.
- • 2,293 investors are based in Boston, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Boston, US
Contact Information
Find more investors like Roman
Search Investors